Journal
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Volume 38, Issue 1, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2023.2191163
Keywords
2-Arylquinazoline; anticancer agents; metalloenzymes; drug design
Ask authors/readers for more resources
In this study, a new series of non-classical CA inhibitors, 2-aryl-quinazolin-4-yl aminobenzoic acid derivatives, were designed and synthesized as potential anticancer candidates. The inhibitory activities of these compounds against different CA isoforms were evaluated, and selected compounds were further tested for their anti-proliferative activity against human cancer cell lines.
As part of our ongoing endeavour to identify novel inhibitors of cancer-associated CA isoforms IX and XII as possible anticancer candidates, here we describe the design and synthesis of small library of 2-aryl-quinazolin-4-yl aminobenzoic acid derivatives (6a-c, 7a-c, and 8a-c) as new non-classical CA inhibitors. On account of its significance in the anticancer drug discovery and in the development of effective CAIs, the 4-anilinoquinazoline privileged scaffold was exploited in this study. Thereafter, the free carboxylic acid functionality was appended in the ortho (6a-c), meta (7a-c), or para-positon (8a-c) of the anilino motif to furnish the target inhibitors. All compounds were assessed for their inhibitory activities against the hCA I, II (cytosolic), IX, and XII (trans-membrane, tumour-associated) isoforms. Moreover, six quinazolines (6a-c, 7b, and 8a-b) were chosen by the NCI-USA for in vitro anti-proliferative activity evaluation against 59 human cancer cell lines representing nine tumour subpanels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available